News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech (RHHBY)'s Immune Therapy Cancer Drug Shows Promise in Early Study


4/11/2013 7:48:11 AM

An experimental drug that spurs the immune system to fight cancer appeared to be safe and demonstrated anti-tumor activity against a variety of cancers in a small early stage study, researchers said on Tuesday. The drug, called MPDL3280A, was discovered and is being developed by Roche's Genentech unit. The Phase 1 trial of the drug in 30 patients with advanced cancer was designed as a dose escalation study to test for toxicity at higher doses. But researchers were also pleased to find early signs of effectiveness of the drug. "We saw clear evidence of anti-tumor activity in a broad range of diagnoses, including lung cancer, kidney cancer, colon cancer and gastric cancer," said Dr. Michael Gordon, who presented the data on Tuesday at the American Association for Cancer Research meeting in Washington, D.C.

Read at Reuters


comments powered by Disqus
Reuters
Genentech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES